Published in Medical Letter on the CDC and FDA, March 11th, 2007
"Emergent BioSolutions remains committed to developing biodefense countermeasures, including anthrax vaccines and immune globulins," said Fuad El-Hibri, chairman and chief executive officer. "This cancellation from NIAID does not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA